In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS, Novartis to co-promote tegaserod and develop compounds

Executive Summary

Bristol-Myers Squibb will co-develop and co-promote (except in Japan) Novartis's Zelmac (tegaserod) to treat irritable bowel syndrome. In return BMS will give Novartis certain rights to two of its drug candidates, CTLA 4Ig and LEA 29Y, in development to stop rejection of transplanted organs.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Product or Technology Swap
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register